Sugi Predict

Sugi Predict / Compounds / SCHEMBL18263281

SCHEMBL18263281

SCHEMBL18263281

CCCC(CBr)CC(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA1A P35348 2/20 0.41
▸ HDAC1 Q13547 2/20 0.41
▸ HDAC2 Q92769 2/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ AKR1A1 P14550 1/20 0.41
▸ CHRM3 P20309 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ GPR84 Q9NQS5 4/20 0.41
▸ TSHR P16473 3/20 0.39
▸ CACNA2D1 P54289 2/20 0.38
▸ CACNB3 P54284 1/20 0.38
▸ CACNA1C Q13936 1/20 0.38
▸ PGR P06401 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ CACNA2D2 Q9NY47 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27805132 1.00 ADRA1A (0.41) ADRA1AHDAC1HDAC2TDP1CHRM1
SCHEMBL18263279 1.00 ADRA1A (0.41) ADRA1AHDAC1HDAC2TDP1CHRM1
SCHEMBL1335604 0.85 ADRA1A (0.48) ADRA1AHDAC1HDAC2TDP1CHRM1
SCHEMBL967149 0.85 ADRA1A (0.48) ADRA1AHDAC1HDAC2TDP1CHRM1
SCHEMBL28994454 0.84 GPR84 (0.58) TDP1GPR84TSHRSLC22A6ALDH1A1
SCHEMBL11294180 0.83 ADRA1A (0.46) ADRA1AHDAC1HDAC2TDP1CHRM1
SCHEMBL940383 0.81 ADRA1A (0.44) ADRA1AHDAC1HDAC2TDP1CHRM1
SCHEMBL7263463 0.81 — —
SCHEMBL23552104 0.80 TSHR (0.37) ADRA1AHDAC1HDAC2TDP1CHRM1
SCHEMBL22245676 0.80 TSHR (0.37) ADRA1AHDAC1HDAC2TDP1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114989061-A Preparation method of brivaracetam 江苏同禾药业有限公司 2022-09-02 — — CN claimed
CN-108503573-B A kind of new preparation method of Bu Waxitan 北京艾百诺医药股份有限公司 2019-11-22 — — CN claimed
CN-108503573-A A kind of new preparation method of Bu Waxitan 北京艾百诺医药股份有限公司 2018-09-07 — — CN claimed
US-12365649-B2 Process for the preparation of brivaracetam ALIVUS LIFE SCIENCES LIMITED (IN) 2025-07-22 — — US disclosed
US-20240199541-A9 PROCESSES TO PRODUCE BRIVARACETAM SUZHOU PENGXU PHARMATECH CO. LTD. (CN) 2024-06-20 — — US disclosed
US-20240010618-A1 PROCESS FOR THE PREPARATION OF BRIVARACETAM ALIVUS LIFE SCIENCES LIMITED (IN) 2024-01-11 — — US disclosed
CN-114805167-B Preparation method of brivaracetam 上海新礼泰药业有限公司 2023-12-19 — — CN disclosed
EP-3302441-B1 PROCESSES TO PRODUCE BRIVARACETAM SUZHOU PENGXU PHARMATECH CO LTD (CN) 2023-12-13 — — EP disclosed
CN-117126092-A Preparation method of brivaracetam 上海上药创新医药技术有限公司 2023-11-28 — — CN disclosed
CN-111170881-B Preparation method of buvaracetam intermediate 上海医药集团股份有限公司 2023-08-01 — — CN disclosed
US-11673862-B2 Processes to produce brivaracetam SUZHOU PENGXU PHARMATECH CO. LTD. (CN) 2023-06-13 — — US disclosed
US-20190152909-A1 PROCESSES TO PRODUCE BRIVARACETAM ESTEVE QUIMlCA S.A. (ES) 2019-05-23 — — US disclosed
US-10221134-B2 Processes to produce brivaracetam ESTEVE QUIMICA S.A. (ES) 2019-03-05 — — US disclosed
CN-108689903-A A kind of new preparation method of Bu Waxitan 北京艾百诺医药股份有限公司 2018-10-23 — — CN disclosed
CN-108503573-A A kind of new preparation method of Bu Waxitan 北京艾百诺医药股份有限公司 2018-09-07 — — CN disclosed
US-20180155284-A1 PROCESSES TO PRODUCE BRIVARACETAM ESTEVE QUIMlCA S.A. (ES) 2018-06-07 — — US disclosed
CN-105646319-B A kind of preparation method of Bu Waxitan 佛山市隆信医药科技有限公司 2018-05-18 — — CN disclosed
EP-3302441-A1 PROCESSES TO PRODUCE BRIVARACETAM Suzhou Pengxu Pharmatech Co., Ltd. (CN) 2018-04-11 — — EP disclosed
WO-2016191435-A1 PROCESSES TO PRODUCE BRIVARACETAM WANG PENG (US) 2016-12-01 — — WO disclosed
CN-105646319-A Preparation method of brivaracetam 佛山市隆信医药科技有限公司 2016-06-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673862-B2 Processes to produce brivaracetam BLVRB, CYP3A4, POR ADRA1A 205/4885HDAC1 1808/4885HDAC2 1186/4885
US-10221134-B2 Processes to produce brivaracetam BLVRB, CYP3A4, POR ADRA1A 205/4885HDAC1 1808/4885HDAC2 1186/4885
US-20190152909-A1 PROCESSES TO PRODUCE BRIVARACETAM BLVRB, CYP3A4, POR ADRA1A 205/4885HDAC1 1808/4885HDAC2 1186/4885
US-12365649-B2 Process for the preparation of brivaracetam CYP2C19, CYP2B6, POR ADRA1A 296/4885HDAC1 1090/4885HDAC2 451/4885
US-20240199541-A9 PROCESSES TO PRODUCE BRIVARACETAM BLVRB, CYP3A4, POR ADRA1A 205/4885HDAC1 1808/4885HDAC2 1186/4885
US-20180155284-A1 PROCESSES TO PRODUCE BRIVARACETAM BLVRB, CYP3A4, POR ADRA1A 205/4885HDAC1 1808/4885HDAC2 1186/4885
US-20240010618-A1 PROCESS FOR THE PREPARATION OF BRIVARACETAM CYP2C19, CYP2B6, POR ADRA1A 296/4885HDAC1 1090/4885HDAC2 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.